Comparing 2022 and Ketoprofene
The two medications 2022 and ketoprofene both have analgesic, anti-inflammatory and antipyretic properties, and are used to treat a range of medical conditions. There are however, some important differences between these two treatments.
2022 is a non-steroidal anti-inflammatory drug (NSAID) which is usually used to treat pain associated with mild to moderate arthritic conditions and other painful conditions such as toothache, backache and dysmenorrhoea. It also has the added benefit of being able to specifically reduce fever. 2022 is a non-selective inhibitor of cyclooxygenase 1 and 2 (COX-1 and COX-2) which means it may cause gastric irritation. These risks can be minimised by taking 2022 with food, using the lowest dose possible and avoiding prolonged use.
Ketoprofene on the other hand is a selective inhibitor of COX-2, meaning it is less likely to eccur certain digestive adverse effects compared to 2022. It is used in the same conditions as 2022 and also has an antipyretic response. Ketoprofene is not recommended for use in children, however in some cases low doses may be given in a monitored setting.
In summary, 2022 and Ketoprofene are similar but there are important differences between them. 2022 is a non-selective inhibitor of COX-1 and COX-2 and therefore has risks of gastric irritation, however it does have the added benefit of reducing fever. Ketoprofene is a selective COX-2 inhibitor and is generally considered to have a lower risk of gastrointestinal adverse effects, however it must not be used in children without strict monitoring.